Premium
Emerging role of anti‐IL23 in the treatment of psoriasis: When humanized is very promising
Author(s) -
Dattola Annunziata,
Silvestri Martina,
Tamburi Federica,
Amoruso Giuseppe F.,
Bennardo Luigi,
Nisticò Steven P.
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14504
Subject(s) - medicine , psoriasis , interleukin 23 , regimen , clinical trial , drug , randomized controlled trial , dermatology , interleukin 17 , pharmacology , immunology , cytokine
Risankizumab is a novel anti‐interleukin 23 humanized antibody developed to treat severe psoriasis. In this paper, we analyze the key information about this new drug and the results of phase 3 clinical trials already present in literature in order measure its safety and effectiveness in every day practice. Risankizumab seems to be one of the best performing drugs in the treatment of psoriasis, with a good safety profile and a dosage regimen less frequent than all other biologic agents, although head‐to‐head randomized clinical trials with other anti‐interleukin treatments will be necessary in order to confirm these preliminary results.